Simpler Grants.gov #PAR-28-072

NIH NEI Translational Research Program for Therapeutics Grant Opportunity

The National Eye Institute (NEI) at NIH is launching a grant opportunity to accelerate the development of therapeutics for diseases and disorders of the visual system. - Government Buyer: - National Institutes of Health (NIH) - National Eye Institute (NEI) - Program Focus: - Translational Research Program (TRP) for rapid translation of laboratory discoveries into therapeutic products - Supports biological, pharmaceutical, medical device, and combination therapies - Award Structure: - Bi-phasic, milestone-driven mechanism - R61 phase: up to two years for research with significant preliminary data - R33 phase: up to four years for preclinical development and IND/IDE enabling studies - Total project duration cannot exceed five years - Requirements: - Advance a single therapeutic candidate through IND/IDE studies, FDA filing, or transition to clinical practice - Specific, measurable milestones required for both phases - Eligibility: - Open to government entities, nonprofits, educational institutions, and businesses - Foreign organizations excluded; foreign components of U.S. organizations allowed under certain conditions - No specific OEMs, vendors, or products are named; opportunity is open to a wide range of applicants

Description

The NEI Translational Research Program (TRP) aims to rapidly translate innovative laboratory research into therapeutics for visual system diseases or disorders. It supports product development of biological, pharmaceutical, medical device, and combination therapies. The program uses a bi-phasic, milestone-driven award mechanism with an R61 phase up to two years and an R33 phase up to four years, totaling no more than five years. The R33 phase focuses on advancing a therapeutic candidate through IND/IDE enabling studies and filing with the FDA. All projects begin with the R61 phase regardless of the therapeutic starting point.

View original listing